Biotechnology Vertex Pharmaceuticals Moves Beyond $10B Cystic Fibrosis Franchise, Pays Around $5B For Kidney Disease Player Alpine Immune Why Alpine Immune Sciences Stock Is Trading Higher Today? – Alpine Immune Sciences (NASDAQ:ALPN), Vertex Pharmaceuticals (NASDAQ:VRTX) Read more
Biotechnology Vertex’s Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept’s Potential Impact – Vertex Pharmaceuticals (NASDAQ:VRTX) Read more
Stockmarkets Vertex Pharma bets on kidney disease treatment with $4.9 billion Alpine Immune deal Reuters via biedexmarkets.com Read more
Venture Capital Attentive, two more startups raise early funding from Khosla Ventures, Vertex, others Read more
Stockmarkets Vertex stock downgraded amid valuation high and pain franchise headwinds By biedexmarkets.com Read more
Biotechnology Vertex Pharmaceuticals’ Triple Combo Treatment For Lung Disorder Meets Primary Goal In Adult And Pediatric Patients – Vertex Pharmaceuticals (NASDAQ:VRTX) Read more
Stockmarkets Vertex non-opioid painkiller meets main goal in late-stage trials Reuters via biedexmarkets.com Read more
Biotechnology Why Is Vertex Pharmaceuticals Stock Sliding Today? – Vertex Pharmaceuticals (NASDAQ:VRTX) Read more